Many large clinical trials have shown promising benefits of SGLT2 inhibitors on cardiovascular and renal outcomes in participants with type 2 diabetes mellitus (T2DM) in addition to its safe and effective glucose‐lowering effects.2, 3, 4, 5. This evidence concerns the gene SLC5A2 and diabetes mellitus.